SurModics Inc. (SRDX)

41.77
NASDAQ : Health Technology
Prev Close 45.87
Day Low/High 41.22 / 45.95
52 Wk Low/High 34.05 / 82.35
Avg Volume 106.70K
Exchange NASDAQ
Shares Outstanding 13.48M
Market Cap 618.42M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Surmodics To Host Virtual Annual Meeting Of Shareholders

Surmodics To Host Virtual Annual Meeting Of Shareholders

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 13, at 4 p.

Surmodics (SRDX) Shares Cross Above 200 DMA

Surmodics (SRDX) Shares Cross Above 200 DMA

In trading on Thursday, shares of Surmodics Inc crossed above their 200 day moving average of $58.34, changing hands as high as $60.66 per share. Surmodics Inc shares are currently trading up about 13.4% on the day.

Surmodics Reports First Quarter Fiscal 2019 Results

Surmodics Reports First Quarter Fiscal 2019 Results

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 first quarter ended December 31, 2018 and updated its financial outlook for...

Surmodics To Webcast First Quarter Fiscal 2019 Earnings Conference Call On January 30

Surmodics To Webcast First Quarter Fiscal 2019 Earnings Conference Call On January 30

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2019 conference call on Wednesday, January...

Surmodics Reports Fourth Quarter Fiscal 2018 Results And Issues Fiscal 2019 Guidance

Surmodics Reports Fourth Quarter Fiscal 2018 Results And Issues Fiscal 2019 Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 fourth quarter ended September 30, 2018, and provided its financial outlook...

12-Month Data From Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented At VIVA 2018

12-Month Data From Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented At VIVA 2018

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that data from the PREVEIL early feasibility study (EFS) of the company's SurVeil ® drug-coated balloon (DCB) was shared in a...

Surmodics Names Teri Sides As Chief Marketing Officer

Surmodics Names Teri Sides As Chief Marketing Officer

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Teri Sides has joined Surmodics as Senior Vice President and Chief Marketing Officer, effective November...

Surmodics To Webcast Fourth Quarter Fiscal 2018 Earnings Conference Call On November 9

Surmodics To Webcast Fourth Quarter Fiscal 2018 Earnings Conference Call On November 9

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2018 conference call on Friday, November 9,...

Surmodics Enters Oversold Territory (SRDX)

Surmodics Enters Oversold Territory (SRDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Surmodics To Present At 7th Annual Intellisight Investor Conference

Surmodics To Present At 7th Annual Intellisight Investor Conference

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will participate in the 7 th Annual Intellisight Conference.

Surmodics Reports Third Quarter Fiscal 2018 Results

Surmodics Reports Third Quarter Fiscal 2018 Results

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 third quarter ended June 30, 2018, and updated its financial outlook for...

Surmodics IVD Launches Breakthrough MatrixGuard™ Diluent

Surmodics IVD Launches Breakthrough MatrixGuard™ Diluent

Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for in vitro diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of MatrixGuard™ Diluent.

Surmodics To Webcast Third Quarter Fiscal 2018 Earnings Conference Call On August 6

Surmodics To Webcast Third Quarter Fiscal 2018 Earnings Conference Call On August 6

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2018 conference call on Monday, August 6, at...

Surmodics Announces Leadership Change And Appointment Of Interim CFO

Surmodics Announces Leadership Change And Appointment Of Interim CFO

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Andrew LaFrence will resign as Chief Financial Officer (CFO) effective May 25, 2018.

Surmodics Acquires Thrombectomy Technology Assets From Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio

Surmodics Acquires Thrombectomy Technology Assets From Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today it has reached an agreement with Embolitech to acquire an innovative thrombectomy platform technology and...

Surmodics Reaches Analyst Target Price

In recent trading, shares of Surmodics Inc have crossed above the average analyst 12-month target price of $41.62, changing hands for $42.35/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

CORRECTING And REPLACING Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance

CORRECTING And REPLACING Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance

The fifth bullet in the Recent Highlights section should read: EPS of $0.11, Non-GAAP EPS of $0.

Surmodics To Webcast Second Quarter Fiscal 2018 Earnings Conference Call On May 2

Surmodics To Webcast Second Quarter Fiscal 2018 Earnings Conference Call On May 2

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2018 conference call on Wednesday, May 2,...

Surmodics Announces FDA Clearance Of A New .018" Low-Profile PTA Balloon Dilation Catheter

Surmodics Announces FDA Clearance Of A New .018" Low-Profile PTA Balloon Dilation Catheter

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it received U.

Surmodics To Present At Upcoming Investor Conferences

Surmodics To Present At Upcoming Investor Conferences

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy...

Surmodics To Host Virtual Annual Meeting Of Shareholders

Surmodics To Host Virtual Annual Meeting Of Shareholders

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 21, at...

Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance

Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 first quarter, ended December 31, 2017, and...

Surmodics To Webcast First Quarter Fiscal 2018 Earnings Conference Call On February 8

Surmodics To Webcast First Quarter Fiscal 2018 Earnings Conference Call On February 8

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2018...

Surmodics Receives 510(K) Clearance For Telemark™ Coronary/Peripheral Support Microcatheter From The U.S. Food And Drug Administration

Surmodics Receives 510(K) Clearance For Telemark™ Coronary/Peripheral Support Microcatheter From The U.S. Food And Drug Administration

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.

Surmodics Reports Fourth Quarter Fiscal 2017 Results And Provides Fiscal 2018 Guidance

Surmodics Reports Fourth Quarter Fiscal 2017 Results And Provides Fiscal 2018 Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 fourth quarter, ended September 30, 2017 and...

Surmodics To Present At Canaccord Genuity Medical Technologies and Diagnostics Forum

Surmodics To Present At Canaccord Genuity Medical Technologies and Diagnostics Forum

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy...

Surmodics To Webcast Fourth Quarter 2017 Earnings Conference Call On November 8

Surmodics To Webcast Fourth Quarter 2017 Earnings Conference Call On November 8

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter 2017 conference...

TheStreet Quant Rating: C- (Hold)